By Ryan Windt | Head of Growth Marketing | Updated June 2026
Life sciences companies sit at the intersection of two things that make cyber attackers move fast: extraordinarily valuable intellectual property and a regulatory environment where a breach is never just an IT problem.
A ransomware attack that locks a biotech company out of its clinical trial database does not just cost money to remediate. It can delay a trial, trigger FDA scrutiny, compromise years of research that cannot be reconstructed from backups, and expose patient data in ways that invite enforcement action from multiple regulators simultaneously. The financial exposure from a single incident can easily exceed the entire annual revenue of an early-stage company.
Generic cyber insurance policies were not designed for that risk profile. This guide covers what life sciences, biotech, and pharmaceutical companies actually need from a cyber policy, how underwriters evaluate this sector, what the coverage gaps look like, and how to build a program that holds up when something goes wrong.
Why Life Sciences Is a High-Target, High-Stakes Sector
The threat environment for life sciences companies is different from most other industries in two structural ways.
First, the value of what you are protecting is disproportionately high relative to your size. A 30-person biotech developing a novel compound has intellectual property worth hundreds of millions of dollars in potential licensing revenue or acquisition value. Nation-state actors and sophisticated criminal groups know this. Attacks targeting research pipelines, drug formulations, clinical data, and regulatory submissions are well-documented and ongoing. The FBI and CISA have issued repeated advisories specifically naming the life sciences sector as a priority target for both financially motivated ransomware groups and state-sponsored espionage.
Second, your regulatory exposure is layered in ways that most industries do not face. A breach involving clinical trial data can simultaneously trigger HIPAA enforcement if patient health information is involved, FDA scrutiny if the integrity of trial data is in question, SEC disclosure obligations if you are a public company, and state attorney general investigations if patient records are compromised. Each of those tracks moves independently, and the costs compound.
The Coverage Gaps That Matter Most
Intellectual Property Theft
Standard cyber policies cover the costs of a breach: forensic investigation, notification, credit monitoring, regulatory defense, and business interruption. What most policies do not cover is the economic value of stolen intellectual property itself.
If a nation-state actor exfiltrates your pre-clinical research, your drug formulation data, or your regulatory submission package, your cyber policy will pay to investigate and remediate the intrusion. It will not compensate you for the competitive advantage you lost when that data ended up in a competitor’s hands. This is a structural gap in the cyber insurance market, not a gap specific to any one carrier.
Understanding this limitation matters for two reasons. It shapes how you prioritize security investments around IP protection specifically, not just breach response. And it affects how you think about policy limits: the right limit for a life sciences company is not determined by your revenue or your IT budget. It is determined by your exposure to the costs of a response, a regulatory action, and an extended business interruption, which can be substantial even without recovering the value of stolen data.
Clinical Trial Data Integrity
A ransomware attack that corrupts or destroys clinical trial data creates a loss that is different from most other business interruption scenarios. The data may not be recoverable. Even if it is technically recoverable, its integrity may be in question in ways that require the trial to be repeated or extended. That can set a development timeline back by years.
Business interruption coverage in a cyber policy pays for lost revenue and extra expenses during the period of interruption. Whether that coverage extends to the full financial impact of a delayed clinical program depends heavily on how the policy defines the period of restoration, how it calculates the business interruption loss for a company that may not yet have commercial revenue, and whether the policy includes contingent business interruption coverage for interruptions caused by third-party vendors such as contract research organizations or cloud providers.
These are policy language questions that need to be examined before you buy, not after a loss.
FDA and Regulatory Response Costs
A breach involving clinical data, drug safety records, or manufacturing system logs can trigger an FDA inquiry even if there is no evidence that data was exfiltrated. The FDA’s interest is in whether the integrity of safety-critical data was compromised, not in whether someone stole it. Responding to that inquiry requires specialized legal and regulatory counsel, and the process can run for months.
Most cyber policies include regulatory defense and fines coverage, but the scope varies. Coverage for HIPAA fines and penalties is common. Coverage specifically designed for FDA enforcement actions is less standardized and worth examining explicitly. For a deeper look at how regulatory fines coverage works across different frameworks, see our post on whether cyber insurance covers regulatory fines.
Manufacturing and OT Exposure
Pharmaceutical manufacturers and medical device companies face a cyber risk layer that pure research organizations do not: operational technology. Manufacturing execution systems, laboratory information management systems, environmental monitoring systems, and quality control systems are increasingly networked and increasingly targeted. An attack that disrupts manufacturing operations, contaminates a batch record, or locks quality systems can trigger a regulatory hold on production that extends far beyond the technical remediation timeline.
Standard cyber policies were designed around IT systems and data. OT coverage is less consistent and often requires explicit negotiation. If your operations include a manufacturing component, the question of whether your policy covers OT system failures and the resulting production losses needs to be answered clearly before you bind.
What Underwriters Are Evaluating
Life sciences underwriting has become more rigorous over the past three years as carriers have accumulated claims experience in the sector. Here is what they are looking at.
Security Posture Around Research Data
Underwriters want to understand how you protect your most valuable data specifically. General security hygiene questions about MFA, EDR, and backups are still on the application, but for life sciences companies, carriers increasingly ask about segmentation of research environments, controls around data exfiltration, access controls for proprietary compound and formulation data, and whether you monitor for unusual data movement patterns.
If you are a company whose crown jewels are a drug pipeline or a novel platform technology, being able to articulate specifically how you protect that data is an underwriting differentiator.
Third-Party and Supply Chain Exposure
Life sciences development is heavily outsourced. Contract research organizations, contract manufacturing organizations, clinical data management vendors, and regulatory affairs consultants all handle sensitive data and have system access. Underwriters want to know what your vendor risk management program looks like: whether you conduct security assessments of key vendors, what your contracts require in terms of security controls and breach notification, and whether a compromise of a CRO or CMO would expose your trial data or your regulatory submissions.
This is an area where preparation pays off. Companies that can document their vendor risk management process get better terms than companies that cannot. For more on how this coverage layer works, see our post on supply chain attacks and cyber insurance.
Incident Response Readiness
Underwriters look at whether you have a documented incident response plan, whether it has been tested, and who leads your response when something goes wrong. For life sciences companies specifically, they also want to know whether your IR plan addresses the FDA notification question: do you know when and how to engage regulators in the event of a breach affecting clinical or manufacturing data?
Backup and Recovery for Research Environments
The backup question for a life sciences company is not just whether you have backups. It is whether your backup architecture protects research data in a way that allows you to verify integrity, not just restore files. Immutable, air-gapped backups of research databases are table stakes for favorable underwriting terms at most carriers writing this sector in 2026.
How Cyber Coverage Is Structured for Life Sciences
A well-structured cyber insurance program for a life sciences company typically includes the following components.
First-Party Coverage
This covers your own losses from an incident: forensic investigation, data restoration, business interruption, cyber extortion, and the costs of notifying affected individuals. For life sciences companies, business interruption coverage deserves close attention because the triggering event and the period of loss can look different than in most industries. A policy that calculates business interruption based on your trailing twelve months of revenue may significantly understate your exposure if your current value is tied to a pipeline that has not yet generated commercial revenue. For a full breakdown of how first and third-party coverage works, see our post on first-party vs. third-party cyber coverage.
Third-Party Liability
This covers claims against you by others: patients whose data was compromised, business partners whose systems were affected by an attack that originated with you, and regulatory bodies. For life sciences companies, this layer needs to address HIPAA liability if you handle patient health information, which most clinical-stage companies do.
Regulatory Defense and Fines
This covers the cost of defending regulatory investigations and, where insurable by law, paying resulting fines and penalties. The insurability of fines varies by jurisdiction and by which regulator is involved. HIPAA civil monetary penalties are generally insurable. GDPR fines may or may not be covered depending on policy language and jurisdiction. FDA enforcement costs are addressed in some policies more explicitly than others.
Cyber Extortion
Ransomware attacks on life sciences companies are well-documented and often involve double extortion: encrypt your systems and threaten to publish your research data or clinical records unless you pay. Extortion coverage pays the ransom if your carrier and legal counsel determine that payment is appropriate. Sublimits on extortion coverage are common and should be reviewed carefully given the leverage attackers have when the threatened publication involves proprietary research or patient data. For more on how sublimits work, see our post on cyber insurance sublimits.
Double extortion attacks on life sciences companies are particularly leveraged because the threatened data often has two separate audiences: competitors who would pay for research data, and regulators who must be notified if patient data is exposed. Attackers understand this and price their demands accordingly.
Coverage Limits: How to Size Your Program
Life sciences companies frequently underinsure because they size their limits based on revenue rather than exposure. An early-stage biotech with $5 million in annual revenue might think $1 million or $2 million in coverage is sufficient. It is not.
The costs that drive a major life sciences cyber event include forensic investigation, regulatory response across potentially multiple agencies, legal defense, business interruption during a period of clinical delay, notification and credit monitoring if patient data is involved, and extortion demands that are often sized to the value the attacker believes you are protecting. Seven-figure incidents are routine. Eight-figure incidents are not rare in this sector.
Sizing your limits requires modeling your actual exposure, not your revenue. For a framework on how to approach that analysis, see our post on how much cyber insurance you need.
Which Carriers Are Active in Life Sciences
Not all cyber insurance carriers have equal appetite or experience in life sciences. The carriers most commonly writing this sector include Coalition, At-Bay, Beazley, Chubb, and Corvus. For earlier-stage companies, Coalition and At-Bay are frequently competitive. For mid-market and larger life sciences organizations, particularly those with manufacturing operations or significant clinical programs, Beazley and Chubb bring deeper experience with the regulatory complexity involved. For a full breakdown of how these carriers compare, see our post on cyber insurance carrier comparison.
The carrier selection question for life sciences is not just about price. It is about which carrier has underwriting appetite for your specific risk profile, which has claims experience in the sector, and which has the capacity to respond at the limits your exposure requires.
Where Life Sciences Fits Within a Broader Insurance Program
Cyber insurance sits alongside, but does not replace, other coverage that life sciences companies carry. Directors and officers liability covers leadership decisions around cybersecurity governance. Errors and omissions covers professional liability claims. A well-structured program ensures these policies coordinate rather than conflict. For technology-forward life sciences companies developing software-enabled diagnostics, AI-assisted drug discovery platforms, or digital health products, the coordination between cyber and technology E&O deserves specific attention. For more on this, see our post on insurance for technology companies.
The overlap between cyber and general liability is worth auditing too. Most GL policies exclude cyber losses, but silent cyber exposures persist in some legacy forms. For a full explanation of how these interact, see our post on whether general liability covers a cyberattack.
Frequently Asked Questions
Does cyber insurance cover stolen drug formulation or research data?
Cyber insurance covers the response costs associated with a data theft event: forensic investigation, regulatory defense, business interruption, and notification. It does not cover the economic value of the intellectual property itself. If a competitor or nation-state actor exfiltrates your proprietary research, your policy pays to respond to the breach, not to compensate for the competitive loss.
What happens if a ransomware attack affects clinical trial data?
Business interruption coverage would apply to the revenue impact and extra expenses during the period of restoration. Whether the policy covers the full economic impact of a delayed clinical program depends on how your policy defines business interruption and calculates the period of loss. For pre-revenue companies, this calculation needs specific attention when structuring the policy, because a trailing-revenue-based formula may significantly understate your exposure.
Does cyber insurance cover FDA enforcement costs following a breach?
Most cyber policies include regulatory defense coverage and, where insurable by law, fines and penalties coverage. Coverage for FDA enforcement specifically varies by policy. Some carriers address this more explicitly than others, and it is worth reviewing policy language carefully if FDA exposure is a material risk for your organization.
How do underwriters treat life sciences companies with no commercial revenue yet?
Pre-revenue biotech and clinical-stage companies can obtain cyber insurance, and several carriers have developed specific approaches for this profile. The underwriting conversation shifts from revenue-based limits to exposure-based modeling, which requires being able to articulate the value of what you are protecting and the potential cost of an incident affecting your clinical program. Working with a broker who has experience placing life sciences accounts helps significantly in framing this for underwriters.
Is cyber insurance required for life sciences companies?
There is no universal regulatory requirement, but cyber insurance is increasingly required by enterprise customers, investors, and contract research organizations as a condition of doing business. Some clinical trial agreements and CRO contracts specify minimum cyber insurance limits. If you are pursuing institutional investment or partnership agreements, expect insurance requirements to be part of the diligence process.
Related Resources
• Cyber Coverage for Healthcare: What HIPAA Doesn’t Cover
• Does Cyber Insurance Cover Regulatory Fines?
• Cyber Insurance Sublimits Explained
• Supply Chain Attacks and Cyber Insurance
• What Underwriters Look for in a Cyber Insurance Application
• How Much Cyber Insurance Do I Need?
• Cyber Insurance Carrier Comparison
SeedPod Cyber works with life sciences, biotech, and pharmaceutical companies to build cyber insurance programs that match the risk profile of the sector. Contact us | Learn about our coverages | See who we work with